TIANDA PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.248 HKD | +0.81% |
|
-4.62% | +13.76% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 547M 70.07M | Sales 2023 | 532M 68.2M | Capitalization | 469M 60.08M |
|---|---|---|---|---|---|
| Net income 2022 | -54M -6.92M | Net income 2023 | -24M -3.08M | EV / Sales 2022 | 1.18 x |
| Net cash position 2022 | 224M 28.73M | Net cash position 2023 | 57.28M 7.34M | EV / Sales 2023 | 0.77 x |
| P/E ratio 2022 |
-15.9
x | P/E ratio 2023 |
-19.4
x | Employees | 863 |
| Yield 2022 |
0.86% | Yield 2023 |
1.19% | Free-Float | 20.57% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.81% | ||
| 1 week | -4.62% | ||
| Current month | -4.62% | ||
| 1 month | +0.81% | ||
| 3 months | +19.23% | ||
| 6 months | +17.54% | ||
| Current year | +13.76% |
1 week
0.24
0.27
1 month
0.240.27
Current year
0.180.28
1 year
0.180.28
3 years
0.150.43
5 years
0.120.43
10 years
0.120.61
| Managers | Title | Age | Since |
|---|---|---|---|
Wen Quan Fang
CEO | Chief Executive Officer | 55 | 02-12-31 |
Tai On Lo
SEC | Corporate Secretary | 69 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sung Hong Chiu
BRD | Director/Board Member | 77 | 08-04-09 |
Yat Fai Lam
BRD | Director/Board Member | 58 | 03-12-31 |
Wen Quan Fang
CEO | Chief Executive Officer | 55 | 02-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 0.248 | +0.81% | 198,000 |
| 24-05-16 | 0.246 | 0.00% | 2,000 |
| 24-05-14 | 0.246 | +0.41% | 40,000 |
| 24-05-13 | 0.245 | -5.77% | 466,000 |
| 24-05-10 | 0.26 | 0.00% | 0 |
Delayed Quote Hong Kong S.E., May 17, 2024 at 04:08 am EDT
More quotes
Tianda Pharmaceuticals Limited is a Hong Kong-based investment holding company principally engaged in pharmaceutical businesses. The main businesses of the Company include the research and development, production and sales of pharmaceutical, biotechnology and healthcare products. Its products include cardio-cerebrovascular drugs, paediatric drugs, anti-flu and respiratory system drugs, anti-infection drugs, medicines for drug addicts and other pharmaceutical products, as well as healthcare products under the Herb Valley series. The Company operates businesses in Hong Kong, China and Australia.
Sector
Pharmaceuticals
Calendar
2024-06-25
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +13.76% | 67.79M | |
| +32.09% | 694B | |
| +29.39% | 593B | |
| -1.34% | 371B | |
| +20.34% | 331B | |
| +7.39% | 290B | |
| +14.25% | 239B | |
| -3.03% | 209B | |
| +10.02% | 209B | |
| +8.49% | 169B |
- Stock Market
- Equities
- 455 Stock
